All cell lines were purchased from ATCC, DSMZ, JCRB or MD Anderson (Minna Lab), except for TM00244, which was purchased as a PDX from Jackson Labs. We generated a stable cell line from TM00244 and confirmed that it retained the
PIK3CA mutation. All cell lines were maintained at 37°C in 5% CO
2 in RPMI (Gibco; Catalog No. 11875–093),
DMEM (Gibco; Catalog No. 11995–065), EMEM (ATCC; Catalog No. 30–2003), or
McCoy’s 5A (ATCC; Catalog No. 30–2007) media and supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% glutamine, except for RERFLCSQ1 and LOU-NH91, which were supplemented with 10% or 20% heat-inactivated fetal bovine serum, respectively. Cells were used within 20 passages from thaw for experiments and were STR profiled and routinely tested for mycoplasma (Lonza
MycoAlert; Catalog No. LT07–703) every 6 months. For
in vitro use,
CC-115 (Selleck Chemicals; Catalog No. S7891) was dissolved in DMSO and clinical grade carboplatin (Rutgers Cancer Institute of New Jersey Pharmacy) was diluted in media. The molecular structure of
CC-115 was previously published (31 (
link)).
Castellano G.M., Zeeshan S., Garbuzenko O.B., Sabaawy H.E., Malhotra J., Minko T, & Pine S.R. (2022). Inhibition of mTORC1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Molecular cancer therapeutics, 21(9), 1381-1392.